M-145

Milnacipran hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant^®

• Formule empirique (notation de Hill): C₁₅H₂₃ClN₂O
• Numéro CAS: 101152-94-7
• Poids moléculaire : 282.81
• Numéro CE : 200-659-6
• Numéro MDL: MFCD27978092
• Code UNSPSC : 41116107
• ID de substance PubChem : 329817879
• Nomenclature NACRES : NA.24

Propriétés

• Qualité: certified reference material
• Forme: liquid
• Caractéristiques: Snap-N-Spike^®/Snap-N-Shoot^®
• Conditionnement: ampule of 1 mL
• Fabricant/nom de marque: Cerilliant^®
• Concentration: 1.0 mg/mL in methanol (as free base)
• Technique(s): gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• Application(s): clinical testing
• Format: single component solution
• Température de stockage: −20°C
• Chaîne SMILES: CCN(CC)C([C@]1(C2=CC=CC=C2)C[C@@H]1CN)=O.Cl
• InChI: 1S/C15H22N2O.ClH/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12;/h5-9,13H,3-4,10-11,16H2,1-2H3;1H/t13-,15+;/m1./s1
• Clé InChI: XNCDYJFPRPDERF-PBCQUBLHSA-N

Description

Description générale

Milnacipran, sold under the brand names Savella^®, Ixel^®, Dalcipran^®, or Toledomin, is a serotonin-norepinephrine reuptake inhibitor (SNRI) used in the treatment of depression. In 2009, the US Food and Drug Administration (FDA) approved milnacipran for management of the chronic pain disorder fibromyalgia, making it only the third drug approved in the US for this indication besides duloxetine and pregabalin.

Application

• Anesthetic and Analgesic Applications of Milnacipran: Review on new serotonin-norepinephrine reuptake inhibitors, highlighting Milnacipran hydrochloride′s role in anesthetic and analgesic applications, discussing its impact on pain management strategies (Fanelli et al., 2021).


• Sustained Release Delivery System for Milnacipran: Development of a novel chitosan-polycaprolactone based mucoadhesive gastro-retentive drug delivery system for Milnacipran HCl, aimed at improving bioavailability and enhancing patient compliance (Hussain et al., 2020).


• Comparative Review of Levomilnacipran and Milnacipran: Analysis of Levomilnacipran′s effectiveness compared to Milnacipran in treating major depressive disorder, focusing on efficacy, tolerability, and patient outcomes (Gautam et al., 2019).


• Antidepressant Efficacy and Side Effects: Network meta-analysis of 21 antidepressants, including Milnacipran, assessing their side effect profiles and comparative tolerability in the acute treatment of major depression (Tomlinson et al., 2019).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Dalcipran is a registered trademark of Pierre Fabre Medicament

Ixel is a registered trademark of Pierre Fabre Medicament

Savella is a registered trademark of Forest Laboratories, Inc.

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Pictogrammes: GHS02,GHS06,GHS08
• Mention d'avertissement: Danger
• Mentions de danger: H225,H301 + H311 + H331,H370
• Conseils de prudence: P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311
• Classification des risques: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• Organes cibles: Eyes
• Code de la classe de stockage: 3 - Flammable liquids
• Classe de danger pour l'eau (WGK): WGK 1
• Point d'éclair (°F): 49.5 °F - closed cup
• Point d'éclair (°C): 9.7 °C - closed cup